Cystic fibrosis microbiology: Advances in antimicrobial therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Waters V;Waters V; Smyth A; Smyth A
  • Source:
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2015 Sep; Vol. 14 (5), pp. 551-60. Date of Electronic Publication: 2015 Feb 28.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101128966 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5010 (Electronic) Linking ISSN: 15691993 NLM ISO Abbreviation: J Cyst Fibros Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam ; New York : Elsevier, c2002-
    • Subject Terms:
      Anti-Bacterial Agents/*administration & dosage ; Cystic Fibrosis/*microbiology ; Respiratory Tract Infections/*drug therapy; Cystic Fibrosis/drug therapy ; Drug Administration Routes ; Humans ; Respiratory Tract Infections/microbiology ; Treatment Outcome
    • Abstract:
      Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to advancements in antimicrobial treatments. New aerosolized antibiotic formulations have recently been introduced (such as inhaled aztreonam), and others are in development (inhaled levofloxacin and liposomal amikacin). Licensed dry powder formulations include tobramycin inhalation powder and dry powder colistimethate (available in Europe). Although inhaled antibiotics have the advantage of being able to deliver high intrapulmonary concentrations of drug, antimicrobial resistance can still develop and is a concern in CF. Antimicrobial resistance might be mitigated by using non-antibiotic treatments, antibiotic adjuvants, which have activity against bacteria. Examples include agents such as gallium, antimicrobial peptides and anti-biofilm compounds such as alginate oligosaccharides (OligoG) and garlic. Vaccination strategies and antibody therapy (IgY) against Pseudomonas aeruginosa have also been attempted to prevent initial infection with this organism in CF. Although aggressive and long-term use of antibiotics has been crucial in slowing lung function decline and improving survival in people with CF, it has added a significant burden of care and associated toxicities in these individuals. Careful surveillance and the use of preventative strategies for antibiotic related toxicity (such as nephrotoxicity and ototoxicity) are essential. Continued development of effective antimicrobial agents that can function in the conditions encountered in the CF lung, such as against bacterial biofilm growth and under anaerobic conditions, is needed.
      (Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
    • Grant Information:
      PB-PG-0213-30055 United Kingdom DH_ Department of Health
    • Contributed Indexing:
      Keywords: Antimicrobials; Cystic fibrosis
    • Accession Number:
      0 (Anti-Bacterial Agents)
    • Publication Date:
      Date Created: 20150305 Date Completed: 20160607 Latest Revision: 20220129
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.jcf.2015.02.005
    • Accession Number:
      25737165